Watch experts decode 'The rise of ESG investing' on October 29 at 4pm. Register Now!
Last Updated : Aug 14, 2019 03:39 PM IST | Source: Moneycontrol.com

Buy Alkem Labs; target of Rs 2180: HDFC Securities

HDFC Securities is bullish on Alkem Labs has recommended buy rating on the stock with a target price of Rs 2180 in its research report dated August 14, 2019.

Broker Research
  • bselive
  • nselive
Todays L/H

HDFC Securities' research report on Alkem Labs

Following a change in the channel filling strategy, we believe 1Q has now become the seasonally weakest quarter for Alkem’s India business, while 2Q and 3Q have become the strongest quarters. This was the key reason for sub-par performance in 1QFY20. India revenues grew 12% YoY to Rs 12.2bn, leading to a 6% miss on our total revenues estimates. We expect India business to grow in double-digits over FY20/21E, in-line with the management’s expectations, driven by sustained growth in both acute and chronic therapies. US revenue at ~US$ 69mn was up 14% YoY, despite incremental competition in gMycophenolate during the last quarter. This was largely driven by higher market share in existing products and continued momentum in new product launches over the last six months. Our FY20 revenue estimates with 6-7% growth are much lower due to the fall we expect in gMycophenolate revenues, albeit the management is confident of achieving double-digit growth for the year. EBITDA at Rs 2.6bn, up 30% YoY was affected by lower India sales and higher than expected bonus component in the employee cost. The margin at 14.3% was up 202/163bps YoY/QoQ. The sequential improvement in gross margin on account of alleviated pricing pressure in raw materials was a key positive takeaway. On a favorable base, PAT grew 36% YoY in 1QFY20.


We maintain BUY on ALKEM despite a big miss on our 1QFY20 estimates. Our TP is 2,180 (22x FY21E EPS) with estimates largely unchanged owing to a sharp recovery expected in the next two quarters following a shift in the seasonally strong quarters (from 1Q earlier to 2Q now).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on Aug 14, 2019 03:39 pm